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After brain injury, astrocytes acquire a reactive phenotype characterized by a series of morpho-
logical andmolecularmodifications, including the expression of the cytoskeletal protein vimentin.
Previous studies have shown that estradiol down-regulates reactive astrogliosis. In this study we
assessedwhether raloxifene and tamoxifen, two selective estrogen receptormodulators, have effects
similar to estradiol in astrocytes.Wealso assessedwhether agingand the timingof estrogenic therapy
after ovariectomy influence the action of the estrogenic compounds. Four groups of animals were
studied: 1) young rats, ovariectomized at 2 months of age; 2) middle-aged rats, ovariectomized at 8
months of age; 3) aged rats, ovariectomized at 18months of age; and 4) aged rats, ovariectomized at
2 months and sham operated at 18 months of age. Fifteen days after ovariectomy or sham surgery,
animals received a stab wound brain injury and the treatment with the estrogenic compounds. The
number of vimentin-immunoreactive astrocytes after injurywas significantly higher in the hippocam-
pus of aged rats after a long-term ovariectomy comparedwith aged animals after a short-term ovari-
ectomy andmiddle-aged rats. In addition, reactive astrocytesweremore numerous in the two groups
of aged animals than in young animals. Despite these differences, the estrogenic compounds reduced
reactive astrogliosis in all animal groups. These findings indicate that estradiol, raloxifene, and tamox-
ifen are potential candidates for the control of astrogliosis in young and older individuals and after a
prolonged depletion of ovarian hormones. (Endocrinology 150: 5010–5015, 2009)
Reactive astrogliosis is a complex phenomenon that in-cludes amixture of positive andnegative responses for
neuronal survival and regeneration. Reactive astroglia
maintain the integrity of the blood-brain barrier and may
contribute to protect the damaged neural tissue but may
also prevent axonal regeneration and increase local in-
flammation (1–4). The identification of factors that reg-
ulate reactive astrogliosis is of practical interest for the
development of therapeutic strategies to reduce neural
damage and promote regeneration after central nervous
system injuries and decrease neuronal death in neurode-
generative disorders. The activation of astrocytes is mod-
ulated by local factors and substances transported by the
systemic circulation, such as the hormones secreted by the
gonads and adrenals, including the ovarian hormone estra-
diol (5). Control of astrogliosis may be one of the mecha-
nismsinvolvedintheneuroprotectiveeffectsofestradiol.The
hormone down-regulates both astroglial proliferation and
themorphological activation of astrocytes after stabwound
brain lesions (6–8), after excitotoxin-induced neurodegen-
eration (9), in an experimental model of Parkinson’s disease
(10), and after lesion of the cholinergic basal forebrain (11).
Estrogen receptors (ERs) are candidate targets for pos-
sible neuroprotective and antiinflammatory therapies
based on estrogen actions. The transcriptional activity of
ERs is regulated by their association with transcriptional
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cofactors that have a tissue or cell-specific expression (12).
This association depends on the three-dimensional con-
formation of the ERs (13), which is modified by different
ER ligands (13–16). Therefore, several ER ligands, known
as selective ER modulators (SERMs), are able to exert
tissue- and cell-specific induction or repression of the ac-
tivity of ERs, acting as ER agonists in some tissues and as
antagonists in others. SERMs may therefore represent an
alternative to estradiol for the treatment or the prevention of
neurodegenerative disorders because they may have estro-
genicneuroprotective actions similar to estradiol in thebrain
andat the sametimeanabsenceofestrogenicactions,oreven
antiestrogenic effects, in other tissues, thus avoiding the pe-
ripheral risks associated with estrogen therapy.
Previous studies have shown that two SERMs that are
in clinical use in humans, raloxifene and tamoxifen, are
able to reduce the activation of microglia induced by the
bacterial endotoxin lipopolysaccharide, in vitro and in
vivo (17, 18). In this study we assessed the effects of 17-
estradiol, tamoxifen, and raloxifene on the number of re-
active astrocytes after a stabwound in the hippocampus of
ovariectomized rats. In addition, a long period of ovarian
hormone deprivation in women increases the risk of neu-
rological disorders, cognitive impairment, or dementia
(19), and it is suspected that aging, the timing after meno-
pause, or both, affect the outcome of estrogen therapy in
postmenopausal women (20, 21). In agreement with this
possibility, studies in rodents have shown that the neuro-
protective actions of estradiol are impaired in reproduc-
tively senescent females (22) and after a prolonged period
of ovarian hormone deprivation (23). Therefore, in the
present study, we also assessed whether aging and the du-
ration of ovarian hormone depletion before estrogen ther-
apies influence the ability of the estrogenic compounds to
reduce reactive astrogliosis.
Materials and Methods
Animals and experimental treatments
Wistar albino female rats from the Complutense University
animal colonywere kept on a 12-h light, 12-h dark schedule and
received food and water ad libitum. Animals were handled in
accordance with the guidelines published in the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Ani-
mals and the principles presented in theGuidelines for the Use of
Animals in Neuroscience Research by the Society for Neuro-
science and following the European Union guidelines (Council
Directive 86/609/EEC). Experimental procedures were ap-
proved by our institutional animal use and care committee. Spe-
cial care was taken tominimize suffering and to reduce the num-
ber of animals used to the minimum required for statistical
accuracy.
Experimental design
In this studyweassessed the effectof estradiol, raloxifene, and
tamoxifen on reactive astroglia in ovariectomized rats. To de-
termine whether the effects of estrogenic compounds are altered
byaging,we studied three groupsof animals: 1) young rats ovari-
ectomized at 2 months of age; 2) middle-aged rats ovariecto-
mized at 8 months of age, and 3) old rats ovariectomized at 18
months of age. All animals received brain injury 15 d after ovari-
ectomy. In addition, to determine whether the effects of estro-
genic compounds in aged animals are altered by the timing of
estrogenic therapy after ovariectomy, another group of rats was
ovariectomized at 2 months of age (i.e. at the same age as the
young animals) and sham ovariectomized at 18 months of age
(i.e. at the same age as the first group of aged animals was ovari-
ectomized) 15 d before brain injury. Thus, both groups of aged
rats were of the same age, 18.5 months, when they received the
brain injury and the treatment with the estrogenic compounds.
BecauseWistar female rats in our colony still maintain relatively
high estrogen levels in plasmaat 18months (689pg/ml1), the
first group of aged rats was deprived of ovarian hormones for
only 15 d before brain injury. In contrast, the second group of
aged rats was deprived of ovarian hormones for 16.5 months
before brain injury.
Brain injury
Animals were bilaterally ovariectomized under halothane
anesthesia (Fluothane;AstraZenecaFarmace´utica,Madrid, Spain).
For brain surgery, animalswere anesthetizedwith halothane and
placed in a stereotaxic apparatus (David Kopf Instruments, Tu-
junga, CA). An incision of the scalp was made and the cranium
exposed. Then a unilateral opening of the skull was made with
a dental drill. A solid stainless steel cannula, with a 0.45-mm
outer diameter, was used to make a longitudinal stab wound in
the left hemisphere. The cannula was positioned at 2 mm lateral
to the midline in young rats, at 2.4 mm lateral to the midline in
middle-aged and aged rats, and at 2 mm posterior to bregma in
all age groups and introduced into the brain until the tip reached
a depth of 5.5 mm. Then the cannula was displaced caudally 3
mm (bregma5mm) and finally removed from the brain. Bleed-
ing was inhibited by compression with a gel-foam sponge. The
scalp wound was sutured with surgical silk.
Treatments with estrogenic compounds
Animals received one sc injection of 17-estradiol (E2758;
Sigma-Aldrich, St. Louis, MO; 100 g/kg), raloxifene (R1402;
Sigma-Aldrich; 1 mg/kg), or tamoxifen (T5648; Sigma-Aldrich;
1 mg/kg) immediately after injury, a second injection 24 h later,
and a third injection 48 h later. Thus, the estrogenic compounds
were administered during the period of glial activation (24). The
dosesof estradiol andestrogenic compoundswere selectedon the
basis of previous studies. This dose of estradiol is known to
stimulate neuroprotective signaling cascades and exert neuro-
protection in the hippocampus (25, 26). These effects may be at
least in part due to the high levels of the hormone achieved
shortly after the injections. The doses of raloxifene and tamox-
ifen were previously shown to be neuroprotective in a model of
excitotoxin-inducedneurodegeneration in vivo (9) and to reduce
microglial activation in a model of brain inflammation (18).
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Tissue fixation and immunohistochemistry
One week after brain injury, animals were deeply anesthe-
tized with pentobarbital (100 mg/kg; Normon Veterinary Divi-
sion, Madrid, Spain) and perfused through the left cardiac ven-
tricle, first with 50ml saline solution (0.9%NaCl) and thenwith
250 ml fixative solution [4% paraformaldehyde in 0.1 M phos-
phate buffer (pH7.4)]. Brainswere removed and immersed over-
night at 4 C in the same fixative solution and then rinsed with
phosphate buffer. Coronal sections of the brain, 50 m thick,
were obtained using a Vibratome (VT 1000 S; Leica Microsys-
tems, Wetzlar, Germany).
Immunohistochemistry was carried out on free-floating sec-
tions under moderate shaking. All washes and incubations were
done in 0.1 M phosphate buffer (pH 7.4) containing 0.3% BSA
and 0.3% Triton X-100. The endogenous peroxidase activity
was quenched for 10 min at room temperature in a solution of
3% hydrogen peroxide in 30% methanol. After several washes
in buffer, sections were incubated overnight at 4 Cwith amono-
clonal antibody for vimentin (diluted 1:500, clone V9; Dako,
Barcelona, Spain), amarker of reactive astrocytes (9), or amono-
clonal antibody for glial fibrillary acidic protein (GFAP; diluted
1:1000; clone GA5; Sigma-Aldrich), a marker of reactive and
resting astroglia. Sections were then rinsed in buffer and incu-
bated for 2 h at room temperature with biotinylated goat anti-
mouse IgG (diluted 1:300; Pierce, Rockford, IL). After several
washes in buffer, sections were incubated for 90 min at room
temperature with avidin-biotin-peroxidase complex (diluted
1:250, ImmunoPure ABC peroxidase staining kit; Pierce). The
reaction product was revealed by incubating the sections with 2
g/ml 3,3-diaminobenzidine (Sigma-Aldrich) and 0.01% hy-
drogen peroxide in 0.1 M phosphate buffer. Then sections were
dehydrated, mounted on gelatinized slides, coverslipped, and
examined with a Leica DMRB-E microscope.
Morphometric analysis
Only brains that showed a complete lesion from the dorsal to
the ventral limit of the dorsal hippocampus were selected for
morphometry. The number of vimentin and GFAP immunore-
active astrocytes was assessed in CA1 and within a distance of
350 m from the lateral border of the wound. The number of
immunoreactive cells was estimated by the optical disector
method (27) using total section thickness for disector height (28)
and a counting frame of 55  55 m. A total of 78 counting
frameswereassessedperanimal. Section thicknesswasmeasured
using a digital length gauge device (Heidenhain-Metro MT 12/
ND221; Traunreut, Germany) attached to the stage of a Leitz
microscope. Cell nuclei from immunoreactive cells that came
into focus while focusing down through the disector height were
counted. All counts were performed on coded sections. The vol-
ume of CA1 was estimated using the point-counting method of
Weibel (29). Because no significant differences in this parameter
were observed among the different experimental groups, the
changes in the number of immunoreactive cells per unit volume
with the optical disector method are assumed to reflect changes
in the total number of immunoreactive cells.
The n used for statistical analysis was the number of animals
(n  4–6). Because the Levene’s test revealed nonhomogeneity
of variances, data were analyzed using the nonparametric
Kruskal-Wallis test followed by the Mann-Whitney test for
paired comparisons, with P 0.05 considered to be significant.
Results
Body weights of the animals at the time of brain surgery are
represented in Fig. 1. Middle-aged and aged animals had a
significantly higher body weight compared with young ani-
mals. Aged animals had a significantly higher body weight
than middle-aged animals. Aged animals that had a pro-
longed depletion of ovarian hormones had a higher body
weight thanagedanimalswith shorter term (15d)depletion.
The qualitative inspection of the sections immuno-
stained for vimentin, todetect reactive astrocytes, revealed
a prominent glial scar along the borders of the wound in
all animal groups. However, animals treated with estra-
diol, raloxifene, or tamoxifen showed a glial scar with a
B
od
y 
w
ei
gh
t (
g)
0
100
200
300
400
500
600
Young  Middle-
Aged
Aged
short
term
OVX
Aged
long
term
OVX
***
***
***
^^^
^^^
+++
FIG. 1. Body weight (grams) of the animals at the time of brain injury.
Young rats, n  21; middle-aged rats, n  23; aged rats after short-
term ovariectomy (OVX), n  17; and aged rats after long-term OVX,
n  19. Data are represented as means  SEM. Significant differences:
***, P  0.001 vs. young values; , P  0.001 vs. middle-aged
values; , P  0.01 vs. aged rats with short-term OVX.
FIG. 2. Panoramic view of the border of the lesion in CA1 showing
representative examples of vimentin immunoreactivity in young rats
after the administration of vehicle (A), estradiol (B), raloxifene (C), and
tamoxifen (D). All figures are at the same magnification. Or, Stratum
oriens; Ra, stratum radiatum.
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lower cellular density compared with control animals
(Figs. 2 and 3). Similar qualitative differences were ob-
served in young, middle-aged, and aged animals.
The morphometric analysis with the optical disector
method confirmed the qualitative observations (Fig. 4).
The administration of estradiol, raloxifene, or tamoxifen
resulted in a significant decrease in the number of reactive
astrocytes in the border of the wound. The decrease in the
number of reactive astrocytes in response to each of the
estrogenic compounds was detected in young, middle-
aged, and aged animals (Fig. 4).
In addition, the morphometric analysis revealed that
both the age and the duration of ovarian hormone deple-
tion affected the number of reactive astrocytes in animals
injected with vehicle (Fig. 4). Thus, a prolonged depletion
of ovarian hormones increased the number of reactive as-
trocytes in aged rats compared with those aged rats that
had a short-term hormone depletion prior injury. The
number of reactive astrocytes was also higher in aged rats
with a prolonged depletion of ovarian hormones than in
middle-aged rats and was higher in both groups of aged
animals than in young animals (Fig. 4).
Significant differences between the experimental
groups were also detected in the number of reactive as-
trocytes after the treatment with estrogenic compounds.
Reactive astrocytes were less numerous in young animals
than in either group of aged animals after the treatment
with estradiol, raloxifene, or tamoxifenand less numerous
in middle-aged animals than in either group of aged ani-
mals after the treatmentwith estradiol and raloxifene (Fig.
4). Furthermore, there were more reactive astrocytes after
estradiol treatment in aged animals with prolonged de-
pletion of ovarian hormones than in those treated after
short-term hormone depletion (Fig. 4).
To exclude the possibility of an effect of estrogenic
compounds on the expression of vimentin, rather than on
the number of reactive astrocytes, we assessed the number
ofGFAP immunoreactive cells inmiddle-aged animals. As
shown in Fig. 5, both estradiol, raloxifene, and tamoxifen
resulted in a significant reduction in the number of GFAP
immunoreactive cells.
FIG. 3. High magnification of vimentin immunoreactive astrocytes in the
CA1 stratum radiatum at a distance of approximately 100–200 m from
the lateral border of the wound. The panels illustrate representative
examples from aged rats ovariectomized 15 d before the brain injury
after the administration of vehicle (A), estradiol (B), raloxifene (C), and
tamoxifen (D). All figures are at the same magnification.
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FIG. 4. Number of vimentin immunoreactive astrocytes per cubic
millimeter within a distance of 350 m from the lateral border of the
wound in animals injected with vehicle (V), estradiol (E), raloxifene (R),
or tamoxifen (T) in young rats (stab wound performed 15 d after
ovariectomy; V, n 5; E, n 5; R, n 6; T, n 5); middle aged rats
(stab wound performed 15 d after ovariectomy; V, n 6; E, n 6; R, n
5; T, n 6); aged rats after short-term ovariectomy (OVX) (stab wound
performed 15 d after ovariectomy; V, n 5; E, n 4; R, n 4; T, n 4),
and aged rats after long-term OVX (stab wound performed 16 months
and 15 d after OVX; V, n 4; E, n 4; R, n 6; T, n 5). Data are
represented as means SEM. Significant differences: *, P 0.05; **, P
0.01; ***, P 0.001 vs. vehicle values, within age groups; , P 0.01;
, P 0.001 vs. young rats, within the same treatment; #, P 0.05;
##, P 0.01; ###, P 0.001 vs.middle aged rats, within the same
treatment;, P 0.01;, P 0.05 vs. aged rats with short-term OVX,
within the same treatment.
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FIG. 5. Number of GFAP immunoreactive astrocytes per cubic
millimeter within a distance of 350 m from the lateral border of the
wound in middle-aged rats injected with vehicle (V; n  6), estradiol
(E; n  6), raloxifene (R; n  5), or tamoxifen (T; n  6). Data are
represented as means  SEM. Significant differences: *, P  0.05;
**, P  0.01 vs. vehicle values.
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Discussion
Previous studies have shown that the systemic adminis-
tration of estradiol to ovariectomized female rats signifi-
cantly decreases reactive gliosis after a stab wound in the
hippocampus (6). Our present findings, using vimentin to
label reactive astrocytes and GFAP to label resting and
reactive astrocytes, confirm these previous observations.
In addition, we have observed that two SERMs currently
used in the clinic, raloxifene, and tamoxifen are also able
to reduce reactive astroglia in the borders of the wound.
Although tamoxifen has been shown to act as an an-
tagonist for several effects of estradiol on neurons (30–
33), our findings suggest that this SERM acts as an estro-
gen agonist in reactive astrocytes. Different expression of
transcriptional coregulators in neurons and astrocytes (12)
or the activation by SERMs of estrogen response element-
independent transcriptional mechanisms in astrocytes (4)
may explain the cell-specific actions of tamoxifen.
We observed that aging increases the number of reac-
tive astrocytes after brain injury in female rats. This par-
allels previous observations in male rats, in which the gli-
otic response after stab wound lesions (34), excitotoxic
damage (35), intracerebral hemorrhage (36), and cerebral
ischemia (37), increases with aging. In addition, we found
that prolonged depletion of ovarian hormones also con-
tributes to increased reactive astrogliosis after brain in-
jury. This is particularly relevant when considering neu-
rodegenerative diseases in women after menopause when
aging is associated with loss of ovarian hormones.
Despite the differences in gliosis after injury, estradiol,
raloxifene, and tamoxifen were able to significantly reduce
the number of reactive astrocytes in all age groups. In addi-
tion, the three estrogenic compounds decreased astrogliosis
inagedratsafteraprolongeddepletionofovarianhormones.
Estradiol, raloxifene, and tamoxifen produced a similar re-
duction in the number of reactive astrocytes in young and
middle-aged animals, which is in agreement with the results
of a recent study showing that estradiol retains its effects on
neuronal survival in thehippocampusofmiddle-aged female
rats in a global ischemia model (38). However, the number
of reactive astrocytes in estradiol and raloxifene-treated an-
imals was higher in aged animals comparedwith young and
middle-aged rats. A prolonged depletion of ovarian hor-
mones also resulted in ahigher numberof astrocytes remain-
ing reactive after estradiol treatment in aged animals. The
increased basal level of astrogliosis with aging and after pro-
longed hormonal depletion may contribute to these differ-
ences. In addition, a previous study in an animal model of
stroke indicated that prolonged depletion of ovarian hor-
mones disrupts both peripheral and central antiinflamma-
toryactionsof estradiol (23).Therefore, it is possible that the
long-term loss of ovarian hormones results in an altered es-
trogenic regulation of both central and peripheral cytokines
and may decrease the protective effects of estrogens in the
aged rats.
In addition to aging and a prolonged depletion of ovar-
ian secretions, body weight at the time of injury is also an
important parameter to take in consideration. Body
weight may affect the pharmacokinetics of estrogenic
compounds andmay affect reactive gliosis because higher
body fat per se is associated with inflammation (39).
Therefore, the observed differences in body weight be-
tween the experimental groups may contribute to the dif-
ferences in astrogliosis after brain injury and after the
treatments with the estrogenic compounds.
In conclusion, estradiol andSERMshaveapotential ther-
apeutic value in controlling astrogliosis after traumatic brain
injury, and thesemayremainbeneficial, even inagedanimals
that have experienced a prolonged depletion of ovarian hor-
mones. The actions of the estrogenic compounds on astro-
cytes may in turn reduce neural damage by decreasing brain
inflammation (4). However, the exact functional conse-
quences of the reduction of astrogliosis in the hippocampus
after a stab wound injury needs to be assessed because reac-
tive astrocytes release substances, including estradiol (40,
41), that promote neuronal survival and remyelination (42).
Therefore, further studies should determine whether the an-
tigliotic effects of estradiol and SERMs are associated with
less neuronal loss or better functional recovery in thismodel.
In addition, the antigliotic effect of estradiol and SERMs on
aged females may be particularly relevant for chronic neu-
rodegenerative diseases associated with aging, in which it is
suspected that a dysfunction of glial cells may contribute to
increased neural damage (43, 44).
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